摘要
恶性淋巴瘤的来源包括不同器官的不同类型的淋巴细胞。随着治疗策略的不断改进,患者的预后也有很大改善。使用基于PET/CT的成像可显著改善分期分类和治疗反应。一线化疗后,基于功能成像结果而进行的治疗规划和疾病活动度分析在放疗方面具有显著意义,并且在治疗区域大小划分和降低毒性方面取得了重大改善。因此,国际淋巴瘤放射肿瘤学小组(ILROG)为治疗计划制定了新的指南,纳入了临床成像指标。功能成像提供的生物学信息使个体治疗计划取代统一的大面积治疗量成为可能,从而进一步减轻不良反应和推动了淋巴瘤治疗的进步。本文将总结FDG-PET/CT成像在恶性淋巴瘤放射治疗规划中的作用。
Improvements of therapeutic strategies have increased long-term survival rates in lymphoma. PET/CT aids tumor classification and staging, monitoring of chemotherapy effect, and optimizing radiation treatment field with decreased toxicity. The International Lymphoma Radiation Oncology Group( ILROG) has developed new guidelines including clinical imaging for treatment planning. PET/CT allows assessment of biological response for individual treatment planning and mitigating side effects. This review article summarizes the effect of18F-FDG PET/CT on radiation therapy planning in malignant lymphoma.
作者
李周雷
陈仲本
LI Zhou-lei;CHEN Zhong-ben(Department of Radiology,The First Affiliated Hospital,Sun Yat-sen University,Guangdong 510080,China)
出处
《影像诊断与介入放射学》
2023年第1期76-78,共3页
Diagnostic Imaging & Interventional Radiology
关键词
正电子发射断层扫描
放疗
淋巴瘤
Positron emission tomography
Radiotherapy
Lymphoma
